T1D Autoantibodies: room for improvement?

Area of Science:

• Endocrinology
• Immunology
• Diabetes Research

Background:

• Type 1 diabetes (T1D) is predictable through measurement of islet autoantibodies (IAbs).
• Key autoantibodies include those against GAD65 (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A).
• Advances in assay technology are crucial for improved T1D prediction.

Purpose of the Study:

• To review the current state of islet autoantibody (IAbs) assay technology for Type 1 diabetes (T1D) prediction.
• To discuss recent advancements and future directions in IAb detection methods.
• To highlight the prognostic value of multiple autoantibodies in T1D development.

Main Methods:

• Review of established radio-binding assays as the gold standard for IAb detection.
• Evaluation of newer nonradioactive electrochemiluminescence (ECL) assays for improved sensitivity and specificity.
• Exploration of multiplexed assays for efficient population screening.

Main Results:

• Radio-binding assays are the established standard for GADA, IA-2A, and ZnT8A.
• Nonradioactive ECL assays demonstrate enhanced sensitivity and disease specificity.
• Multiplexed assays offer potential for large-scale, efficient screening.
• Emerging research focuses on novel autoantibodies and neo-epitopes.

Conclusions:

• A single positive autoantibody indicates low T1D risk.
• Two or more positive autoantibodies, especially over time, predict nearly 100% risk of clinical T1D.
• Development of efficient, cost-effective IAb assays is essential for point-of-care screening in the general population.